Burning Rock Biotech (BNR) EBT (2019 - 2026)

Burning Rock Biotech's EBT history runs 8 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, EBT fell 36.43% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$8.2 million (up 74.44% YoY), while the FY2025 annual figure was -$7.7 million, up 83.52% from the prior year.
• EBT for Q1 2026 stood at -$2.5 million, down from -$2.1 million in the prior quarter.
• The five-year high for EBT was -$1.3 million in Q2 2025, with the low at -$41.2 million in Q1 2022.
• The 5-year median for EBT is -$16.8 million (2024), against an average of -$17.2 million.
• The sharpest annual moves came in 2022 and 2025: EBT sank 57.61% in 2022, then soared 91.11% in 2025.
• Burning Rock Biotech's EBT stood at -$31.1 million in 2022, then grew by 26.96% to -$22.7 million in 2023, then soared by 54.14% to -$10.4 million in 2024, then jumped by 80.07% to -$2.1 million in 2025, then slipped by 20.44% to -$2.5 million in 2026.
• Business Quant data shows BNR's EBT at -$2.5 million in Q1 2026, -$2.1 million in Q4 2025, and -$2.3 million in Q3 2025.